Figure 3
SS with CS peptide in AddaVax, with or without TLR 7 agonist imiquimod or TLR 3 agonist poly I:C, elicits primarily a Th2-type response and minimal protection.
(A) Kinetics of IgG anti repeat antibody GMT measured by ELISA using individual serum (5 mice/group) obtained following four SS immunizations (arrows) with CS peptide in Aldara, containing the TLR7 agonist imiquimod, or in AddaVax with or without addition of TLR 7 agonist imiquimod or TLR 3 agonist poly I:C. (B) IgG subtypes of anti-repeat antibodies in pooled serum (1:320 dilution) obtained following four SS doses with peptide in Aldara or Addavax with or without imiquimod or poly I:C. (C) IFNγ ELISPOT (upper panel) and IL-5 ELISPOT (lower panel) of pooled spleen cells (3 mice/group) obtained following four SS immunizations. Results shown as SFC/106 spleen cells in the absence (solid bars) or presence of MAB anti-CD4 or anti-CD8 (hatched bars). (D) Mice were challenged by exposure to the bites of PfPb infected mosquitoes following four SS immunizations. Results shown as mean 18 S rRNA copy number in liver extracts prepared 40 h post infection as measured by qPCR. Kruskal-Wallis test with Dunn’s multiple comparison between groups against naïve; no significant difference was detected between groups. Error bars are SD for all qPCR replicates.
